Article

Additional Value of [18F]FDG PET/CT in Detection of Suspected Malignancy in Patients with Paraneoplastic Neurological Syndromes Having Negative Results of Conventional Radiological Imaging

Marta Opalińska 1, Anna Sowa-Staszczak 2,*, Kamil Wężyk 3, Jeremiasz Jagiełła 4, Agnieszka Słowik 4 and Alicja Hubalewska-Dydejczyk 2

Abstract: Background: Paraneoplastic neurological syndromes (PNS) affecting the CNS (central nervous system) are rare, presenting in less than 1% of all those with cancer. The pathogenesis of paraneoplastic neurological syndromes is not fully understood, but it is presumed to result from an immune attack on the underlying malignancy. The presence of different types of onconeural antibodies may occur in different tumors and can lead to different clinical manifestations, making the early detection of cancers challenging. Aim: An evaluation of [18F]FDG PET/CT in neoplastic tumor detection in patients with paraneoplastic neurological syndromes having negative or unremarkable results of conventional radiological imaging. Methods: Among all patients diagnosed with paraneoplastic neurological syndromes in the Neurology Department in 2016–2020, 15 patients with unremarkable conventional radiological findings who underwent [18F]FDG PET/CT were included in the study. Results: [18F]FDG PET/CT enabled localization of suspected malignancy in 53% (8 of 15) of PNS cases with previous unremarkable conventional radiological findings. Conclusion: [18F]FDG PET/CT may be considered as a useful tool for neoplastic tumor detection in patients with paraneoplastic neurological syndromes, accelerating the diagnostic process and enabling faster initiation of appropriate treatment.

Keywords: paraneoplastic syndromes; neurooncology; [18F]FDG PET/CT; PNS

1. Introduction

Paraneoplastic syndromes represent a wide range of symptoms associated with malignancy. They are usually systemic dysfunctions which are not a direct result of neoplastic tumor invasion or metastasis. They may manifest with symptoms from various systems and organs, causing endocrine, neurological, dermatological, rheumatological and hematological syndromes, usually, in areas and organs that are not directly affected by the neoplasm. The most common malignancies associated with paraneoplastic syndromes include breast, lung, pancreas, kidney as well as gynecological and hematological tumors. The incidence and prevalence of paraneoplastic disorders is estimated to be 0.89/100,000 person-years and 4.4 per 100,000, respectively [1]. In many cases, the etiology of the syndrome is unknown. Most often, they are autoimmune reactions to circulating tumor antigens or an effect of biologically active substances, such as hormones, growth factors or cytokines secreted by tumor cells.
Paraneoplastic neurologic syndromes (PNS) in the large majority respond well to the symptomatic therapy; however, not in all cases is such treatment effective. The population-based study estimated an incidence of PNS at about 1/100,000 person-years and a prevalence of 4/100,000, with the incidence ratio increasing over time [2]. The clinical presentation of PNS is excessively variable (Table 1); hence, the proper diagnosis requires extensive workup and clinical experience. In 2004, an international panel of experts recommended diagnostic criteria defining a neurological syndrome as a paraneoplastic syndrome based on the coexistence of onconeural antibodies and the presence of clinical symptoms. Further, they categorized those presentation as “classical” and “non-classical” syndromes. “Classical” syndromes (e.g., Lambert–Eaton myaesthenic syndrome, limbic encephalitis, encephalomyelitis, subacute cerebellar degeneration, sensory neuronopathy, dermatomyositis, or opsoclonus-myoclonus) are more likely to be associated with an underlying malignancy [3].

According to the current knowledge, PNS occur in two main mechanisms of immune response. The first is the direct immune response against neuronal receptors or other cell membrane antigens. The most common types of abovementioned antibodies and their clinical significance are summarized in Table 2. Those syndromes usually present clinically by rapidly developing neurological dysfunction, which might not be related to tumor size or growth and frequently respond well to anti-inflammatory treatment. In the second type, the immunoreactivity is triggered by intra-cellular neuronal proteins, which are more often associated with the development of malignancy. In that mechanism, the immune response targets originate from intracellular antigens/proteins revealed by neuronal death. In those conditions, neurological damage is usually more severe and very often irreversible. The most common types of antibodies against intra-cellular neuronal proteins, associated with underlying malignancy, and their clinical symptoms are summarized in Table 3.

However, tumor removal itself is very seldom linked with good prognosis (e.g., teratoma removal in patients with NMDA (Anti-N-methyl-d-aspartate-mediated encephalitis) [4]), prompt identification and treatment are strongly recommended in order to eliminate proteins triggering the immune response (e.g., small cell carcinoma with anti Hu [5]). Within the pursuit of identifying the origin of malignancy, early imaging using radiological procedures (CT or MRI) often fails to establish the diagnosis. Among the widely available methods of advanced diagnostic procedures, a whole-body [18F]FDG PET/CT might be indispensable in the search for underlying pathology.

In the current state of knowledge, the value of [18F]FDG PET/CT as a pivotal imaging in doubtful cases is recommended but not fully elucidated. The rarity and complexity of neurological PNS leads to a paucity of information necessary to formulate strong diagnostic recommendations.

Table 1. Paraneoplastic syndromes of the nervous system classified by location. Adapted from Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008; 7(4): 327–340. [6].
Table 2. Major paraneoplastic onconeuronal antibodies reactive with neuronal membrane antigens. Adapted from Galli, J.; Greenlee, J. Paraneoplastic Diseases of the Central Nervous System [7].

| Antibody                     | Common Neurological Phenotypes | Common Associated Malignancies |
|------------------------------|-------------------------------|-------------------------------|
| Anti-AMPAR                   | Limbic encephalitis           | Breast                        |
|                              |                               | Lung                          |
|                              |                               | Thymus                        |
| Anti-LGI1/Anti-CASPR2        | Limbic encephalitis           | Thymoma (especially in patients positive for both antibodies) |
|                              | Faciobrachial dystonic seizures | Other neoplasms (rare)       |
| Anti-GABAβR                  | Limbic encephalitis, status epilepticus | Small-cell lung cancer |
| Anti-mGluR1                  | Cerebellar degeneration       | Hodgkin’s disease             |
| Anti-mGluR2                  | Cerebellar degeneration       | Small-cell; alveolar rhabdomyosarcoma |
| Anti-mGluR5                  | Limbic encephalitis           | Hodgkin’s disease             |
| Anti-VGKC                    | Cerebellar degeneration       | Small-cell lung cancer        |
|                              | (Lambert–Eaton myasthenic syndrome) |                              |

Table 3. Major paraneoplastic onconeuronal antibodies reactive with intracellular neuronal antigens. Adapted from Galli, J.; Greenlee, J. Paraneoplastic Diseases of the Central Nervous System [7].

| Antibody                     | Common Neurological Phenotypes | Common Associated Malignancies |
|------------------------------|-------------------------------|-------------------------------|
| Anti-CRMP5                   | Optic neuritis                | Small-cell lung cancer        |
|                              | Cerebellar degeneration       | Breast                        |
|                              | Encephalomyelitis             |                               |
| Anti-GAD65                   | Stiff person syndrome         | Thymoma                       |
| (ANNA-1)                     | Limbic encephalitis           | Renal cell carcinoma          |
|                              | Cerebellar ataxia             |                               |
| Anti-Hu (ANNA-1)             | Limbic encephalitis,          | Small-cell lung cancer        |
|                              | encephalomyelitis, dorsal      | Neuroendocrine tumors         |
|                              | sensory neuropathy            | Retinoblastoma (infants)      |
| Anti-Ma1                     | Limbic or brain-stem          | Non-small-cell lung cancer;   |
|                              | encephalitis                  | other                         |
| Anti-Ma2                     | Limbic or brain-stem          | Testicular or other germ cell | Non-small-cell lung cancer |
|                              | encephalitis                  | tumors                        |
| Anti-Ri (ANNA-2)             | Cerebellar degeneration       | Breast                        |
|                              | opsoclonus myoclonus,         |                               |
|                              | brain-stem encephalitis       | Small-cell lung cancer        |
| Anti-Tr                      | Cerebellar degeneration       | Hodgkin’s disease             |
| Anti-Yo (PCA-1)              | Cerebellar degeneration       | Ovary, uterus, adnexa         |
|                              |                               | Breast                        |

The aim of the study was to assess the usefulness of [18F]FDG PET/CT in patients with high risk of PNS and negative or unremarkable results of conventional radiological imaging.

2. Methods

Among the patients diagnosed with neurological syndromes between 2016–2020 in the Neurology Department of University Hospital in Krakow, we selected cases with a clinical picture strongly suggesting an underlying neoplastic background (rapid course of PNS and resistance to conventional first-line treatment).

In 15 of them, with positive or unremarkable results of onconeuronal antibodies, due to negative or unambiguous results of conventional screening (including radiological and endoscopy workup), the [18F]FDG PET/CT was applied.
Among these patients, seven were diagnosed with classical neurological PNS (cerebellar degeneration—3 cases, sensory polyneuropathy—1 case, autoimmune encephalitis—3 cases), and 7 with non-classic PNS (myasthenia gravis (MG)—1, myelitis—1, motor neuron disease—1, sensorimotor polyneuropathy—4). Additionally, a patient with Primary Angiitis of Central Nervous System (PACNS) (1) was included in the analysis, since several cases of sporadic presentation of that disease as a paraneoplastic syndrome are available in the literature.

All patients’ demographic data, clinical presentation, cerebrospinal fluid (CSF) evaluation, previous imaging results and onconeuronal antibodies screening were recorded from the available patient database. The distribution of PNS types diagnosed among the analyzed group is presented in Table 4.

Table 4. The distribution of PNS types diagnosed among the analyzed group and the results of [18F]FDG examination.

| Classic PNS                                | No of Patients with PNS Included to Analysis | No of Patients with Positive [18F]F-FDG PET/CT Findings | Percentage of PET/CT Positive Examination |
|--------------------------------------------|---------------------------------------------|--------------------------------------------------------|------------------------------------------|
| Cerebellar degeneration                     | 3                                           | 3                                                      | 100                                      |
| Sensory polyneuropathy                     | 1                                           | 0                                                      | 0                                        |
| Autoimmune encephalitis                    | 3                                           | 1                                                      | 33                                       |
| Non-classic PNS                            |                                             |                                                        |                                          |
| Myasthenia gravis                          | 1                                           | 1                                                      | 100                                      |
| Myelitis                                   | 1                                           | 1                                                      | 100                                      |
| Sensorimotor polyneuropathy                | 4                                           | 2                                                      | 50                                       |
| Motor neuron disease                        | 1                                           | 0                                                      | 0                                        |
| Others                                     |                                             |                                                        |                                          |
| Primary Angiitis of Central Nervous System (PACS) | 1                                           | 0                                                      | 0                                        |
| Sum                                        | 15                                          | 8                                                      | 53                                       |

2.1. Image Acquisitions and Analysis

[18F]FDG PET/CT examinations were conducted in accordance with the standard protocol on GE DISCOVERY 690 VCT scanner (Krakow, Poland). All patients fasted at least 6 h before the procedure. Bedside fasting blood glucose of more than 11.0 mmol/L was not accepted. Imaging was performed 60 min after intravenous administration of the radiotracer. An initial low-dose CT without contrast enhancement (Smart mA with range: 50–180 mA) was performed, in order to correct for photon attenuation and to co-localize FDG uptake and anatomical structures. The FDG PET/CT was performed from the mid-thigh to the top of the head. Patients received 4 MBq [18F]FDG per 1 kg body mass (2 min per bed position in three-dimensional mode). The PET data were reconstructed with the use of the GE (matrix size 128 × 128, Vue Point FX reconstruction method: 16 subsets, 3 iterations reconstruction algorithm). Corrections were applied for attenuation, dead time, scatter and random coincidences. All image analyses were performed on fused PET/CT data sets. Slice thickness of the PET short-axis images was 3.3 mm. The estimated dose of radiation per patient was about 9.5 mSv.

All images were reviewed using first attenuation-corrected images. In all cases, a senior nuclear medicine consultant made an initial assessment of [18F]FDG-PET scans, which was then re-assessed by the consultant radiologist.

The PET/CT was binary classified, so a positive result was defined as the presence of a metabolically active tumor of any region of body, suspicion of metabolically active dissemination of neoplastic disease or increased focal uptake, being highly suspected to correspond with malignancy.
The negative results were considered as scans with no FDG uptake, and with any focal increased uptake with intensity higher than the surrounding tissues, but in localization not highly suspicious as a malignancy.

2.2. Statistical Analysis

Demographic and clinical characteristics were analyzed by producing tables of frequency for categorical variables and by calculation of the median and range for continuous variables. IBM SPSS Statistics for Windows, version 27 (IBM Corp., Armonk, NY, USA) was employed for the statistical analysis.

3. Results

A group of 15 patients (9 females and 6 males) were eligible for the study. The median age was 70 years (range: 32–88 years). All patients underwent anatomical neuroimaging of the brain—in 5 cases, head CT and in the remaining cases, MRI. A total of 14 patients also underwent lumbar puncture; in one patient, due to lack of consent, only blood tests were performed. The whole group was evaluated for the presence of onconeuronal antibodies [Table 5]. Positive results of [18F]FDG PET/CT were found in 8 out 15 cases, which were associated with 4 types of neurological PNS.

The following percentages of positive results were found: in patients with myelitis 100% (1 case), cerebral degeneration 75% (3 of 4 cases) and among patients with polyneuropathies 50% (2 of 4 cases).

Among patients with myasthenia gravis, primary angiitis of the central nervous system and motor neuron disease there were no positive results of PET/CT (total number of observations: 4). The increased FDG uptake was found in 4 cases in lungs, in 1 case in colon, in 2 cases in lymph nodes of neck and chest and in 1 case in stomach (Figure 1).

![Figure 1. MRI and PET/CT results of a patient with cerebellar degeneration. (A,B) nonspecific vascular demyelination detected on MRI. (C,D) metabolically active area in the pylorus and in the locoregional lymph nodes detected on [18F]FDG PET/CT.](image-url)
| Patient No | Sex, Age | Neuroimaging (CT, MR) | CSF Results | Antibodies | Metabolic Abnormalities of CNS | PET/CT Abnormalities |
|------------|---------|-----------------------|-------------|------------|-------------------------------|---------------------|
| 1. F. 88   |         | Brain MRI: nonspecific vascular demyelination; no clinical relevance | Cytosine 0.005 × 10^3 /µl | Protein 45.3 mg/dL (20.00–40.00) | oligoclonal bands: positive | anti-Yo none | metabolically active area in the pylorus and metabolically active lymph node next to the pylorus SUV max 7.8 |
| 2. F. 83   |         | Brain MRI: leucomalacia around lateral ventricles. Nonspecific vascular demyelination. Moderate cortical atrophy—mainly posterior. Bilateral hypointense changes in the thalamus and caudate nuclei on diffusion weighted imaging (DWI). | Cytosine 0.004 × 10^3 /µl | Protein 54.8 mg/dL (20.00–40.00) | oligoclonal bands: negative | anti-NMDA anti-Yo | Generalized cortico-subcortical atrophy of the brain. metabolically active lymph nodes in the mediastinum and chest—suspicion of lymphoma. SUV max 10.5 |
| 3. M. 66   |         | Brain MRI not performed (due to contraindications) | not detected | not detected | oligoclonal bands: positive | anti-Yo none | metabolically active tumor in the transverse colon SUV max 5.0 |
| 4. F. 32   |         | Brain MRI normal | Cytosine 0.008 × 10^3 /µl | Protein 26.3 mg/dL (20.00–40.00) | oligoclonal bands: negative | anti-NMDA none | increased metabolism of FDG in the topography of numerous lesions in both lungs. SUV max up to 7.5 |
| 5. M. 30   |         | Brain MRI: demyelinating lesions located bilaterally in the white matter of the frontal and parietal lobe, in the periventricular and subcortical areas. | Cytosine 0.002 × 10^3 /µl | Protein 47.2 mg/dL (20.00–40.00) | oligoclonal bands: negative | anti-NMDA none | not significant |
| 6. F. 74   |         | Brain MRI: ependymal cyst located anteriorly from the medulla oblongata, on the left side numerous demyelinating lesions located in the white matter of the centrum semiale, periventricular and periventricular areas; numerous, small signal loss zones on Susceptibility-Weighted Imaging (SWI) which correspond to the presence of haemosiderin deposits—after microhemorrhages | Cytosine 0.002 × 10^3 /µl | Protein 73.7 mg/dL (20.00–40.00) | oligoclonal bands: positive | anti-NMDA anti-Yo | cortical-subcortical atrophy of the brain not significant |
| 7. F. 79   |         | Brain MRI: nonspecific vascular demyelination; no clinical relevance | not performed | anti-ACSR | areas of punciformity with decreased FDG metabolism | not significant |
| 8. F. 70   |         | Cervical Spine MRI | Cytosine 0.003 × 10^3 /µl | Protein 74 mg/dL (20.00–40.00) | oligoclonal bands: negative | anti-AQP4 none | moderately metabolic active tumor in segment 4/5 of the right lung. SUV max 3.5 |
| 9. M. 59   |         | Brain MRI not performed. Brain CT normal | not performed | not detected | none | anti-PNMA2 (Ma2/Ta) | metabolically active tumor in the apex of the left lung with the involvement of homonymous mediastinal lymph nodes—in SUV max 9.4 |
| 10. F. 56  |         | MRE not performed. Brain CT normal | not performed | not detected | none | anti-PNMA2 (Ma2/Ta) | metabolically active tumor in the apex of the left lung in the left part of the neck and in the upper mediastinum. SUV max 5.7 |
| 11. F. 73  |         | Brain MRI not performed. Brain CT normal | Cytosine 0.003 × 10^3 /µl | Protein 144.1 mg/dL (20.00–40.00) | oligoclonal bands: negative | anti-PNMA2 (Ma2/Ta) anti-CV2.1 | None | metabolically active cervical lymph node and a metabolically active soft tissue mass in the lower part of the neck and in the upper mediastinum. SUV max 5.7 |
| 12. M. 69  |         | Brain MRI: nonspecific vascular demyelination; no clinical relevance. | not performed | anti-PNMA2 (Ma2/5a) | none | | not significant |
| 13. M. 65  |         | Brain MRI: nonspecific vascular demyelination; no clinical relevance. | Cytosine 0.002 × 10^3 /µl | Protein 187 mg/dL (20.00–40.00) | oligoclonal bands: negative | | lesions in the 1 + 2 segment of left lung SUV max 2.2 |
| 14. M. 38  |         | Brain MRI: disseminated demyelinating lesions located in the cortico-subcortical area of the right insula. Bilaterally in the corona radiata and single irregular lesions with cortico-subcortical distribution. | Cytosine 0.004 × 10^3 /µl | Protein 36.2 mg/dL (20.00–40.00) | oligoclonal bands: negative | | anti-Yo none | nonspecific segmental metabolic stimulation in the loops of the small intestine. SUV max 7.7 |
| 15. F. 47  |         | Cervical Spine MRI: multi-level discopathy without pressure on the surrounding nerve roots. | Cytosine 0.001 × 10^3 /µl | Protein 67.86 mg/dL (20.00–40.00) | oligoclonal bands: negative | anti-Yo none | | not significant |
The mean value of SUV max in pathological findings were 6.59 (range 2.2–10.5).

The [18F]FDG PET/CT findings along with patients’ demographic information, clinical presentation, results of brain/spinal cord imaging, presence and type of onconeural antibodies, and CSF analysis results are summarized in Table 5.

### 4. Discussion

PNS are rare (less than 1%) manifestation of malignancy. However, its significance is greater, because of diagnostic difficulties and demanding therapeutic process. Due to the increased availability of onconeural antibody tests, there is a progress in both early diagnosis and the implementation of effective targeted therapy.

According to published guidelines for PNS diagnosis [8] in all cases tumor removing is indicated, increasing chance for proper control of PNS symptoms. In patient (No. 4), the neurological symptoms including involuntary movements and psychotic symptoms, were refractory to therapy with steroids, intravenous immunoglobulins and monoclonal anti-CD20 antibody. Only identification and resection of the papillary thyroid cancer led to remission, however PET/CT examination revealed dissemination.

Other risk factors of neurological autoimmune disorders such as coexisting autoimmune disease or a family history of autoimmunity may mislead the initial diagnosis, but in all cases, exclusion of malignancy is mandatory. The evaluation of serum cancer markers such as CA-125, CA-15.3, prostate-specific antigen, and carcinoembryonic antigen with subsequent CSF assessment are usually the first steps in diagnostic workup. In our cohort, only one patient (No. 10) had an elevated carcinoma antigen 15-3 (Ca 15-3), suggesting an underlying paraneoplastic syndrome; however, the [18F]FDG PET/CT result was negative.

In many patients, CSF analysis demonstrates abnormalities such as elevated protein, pleocytosis, the presence of oligoclonal bands or mixed abnormalities, but normal CSF analysis results do not exclude the possibility of PNS [9]. Patients No. 2, 4 and 14 had normal CSF findings, although other elements of the clinical picture indicated the possibility of PNS. Finally, only in the patient with cerebellar syndrome (No. 2) did the PET/CT scan show metabolically active lymph nodes in the mediastinum and chest, suggesting myeloproliferative syndrome.

Onconeural antibodies may act as markers for the specific tumors, e.g., anti-Yo for breast or reproductive system tumors, anti-Hu for small-cell lung cancer, anti-Ri for breast or lung or anti-Ma2 for testicle malignancy. In these cases, targeted tumor seeking by CT, mammography, pelvic or testicular ultrasound is essential. However, in cases with high risk of malignancy established by the presence of antibodies directed against intracellular neuronal proteins and adequate clinical presentation, PET/CT with [18F]FDG may bring additional benefits due to the high sensitivity of PET/CT in the detection of small, aggressive tumors. Furthermore, many types of PNS and onconeural antibodies can appear in several types of tumors, such as Anti-Yo antibodies which were found in patients with cerebellar syndrome (No. 1, 2), primary CNS vasculitis (No. 14) and motor neuron disease (No. 15). In this context, in cases with positive, unspecific for particular malignancy, antibodies, PET/CT may have additional value, enabling whole-body screening during a single examination.

The meta-analysis evaluating the suitability of [18F]FDG PET/CT in PNS demonstrated a pooled sensitivity of 0.81 and specificity of 0.88 in patients with suspicion of paraneoplastic syndrome [10]. However, that high pooled sensitivity results from data analysis of all patients with PNS having both positive and inconclusive/negative results of prior conventional imaging. In our study, the efficacy of [18F]FDG PET/CT was 53%, but only patients with negative previous radiological and endoscopic exams were evaluated in whom PET/CT had a real clinical benefit.

In the clinical context, it is worth considering if and when PET/CT should be repeated in case of a negative initial study. The guidelines recommend regular oncological surveillance every 6 months for up to 4 years [11] for initially negative imaging results;
however, prolonged time of observation may be connected with unfavorable outcomes in some patients.

The worsening of a known autoimmune syndrome or the occurrence of a new one may suggest dissemination or recurrence of the malignancy. In two patients (No. 3 and 8), the PET/CT exam was repeated (after 12 and 3 months, respectively) due to progressing clinical symptoms. In patient 8 the second exam revealed lung malignancy.

Several studies have shown that whole-body [18F]FDG-PET and [18F]FDG PET/CT are very useful in the screening of patients with suspected paraneoplastic syndrome and positive paraneoplastic antibodies [12]. However, a recent study conducted by another group suggested that the presence of paraneoplastic antibody should not be an indispensable factor for performing [18F]FDG PET/CT [13,14]. In our study, the effectiveness of [18F]FDG PET/CT in the detection of pathology in patients with the presence and absence of onconeural antibodies and clinical presentation highly suggesting malignancy, PET/CT scans were positive. Furthermore, in total, there were 53% of positive [18F]FDG PET/CT results (50% and 57% of patients with non-classical and classical PNS, respectively).

The results of our study indicate the potential benefits of [18F]FDG PET/CT in a routine neurological practice in selected patients with PNS, regardless of their onconeural antibody status and type of PNS.

5. Highlights

[18F]FDG PET/CT may be effective in malignancy detection in a large group of PNS patients with negative results of prior diagnostic procedures.

In a routine neurological practice, selected patients with PNS may benefit from [18F]FDG PET/CT regardless of their onconeural antibody status and type of PNS.

Repeating [18F]FDG PET/CT may have additional value, but the optimal timing for the second examination remains uncertain.

Author Contributions: M.O.: Data collection, imaging review, data analysis, manuscript drafting, manuscript editing and approval, study coordination. A.S.-S.: Data collection, imaging review, data analysis, manuscript drafting, manuscript editing and approval. K.W.: Data collection, imaging review, manuscript drafting, manuscript editing and approval. A.S.: Analysis and interpretation of data, manuscript editing and approval. J.J.: Analysis and interpretation of data, manuscript editing and approval. A.H.-D.: Imaging review, data analysis, analysis and interpretation of data manuscript, editing and approval. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The study protocol was approved by the Local Ethics Committee of the Jagiellonian University in Krakow (approval no 1072.6120.162.2021).

Informed Consent Statement: Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Data Availability Statement: All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Devine, M.F.; Kothapalli, N.; Elkhooly, M.; Dubey, D. Paraneoplastic neurological syndromes: Clinical presentations and management. Ther. Adv. Neurol. Disord. 2021, 14, 1756286420985323. [CrossRef] [PubMed]
2. Vogrig, A.; Gigli, G.L.; Segatti, S.; Corazza, E.; Marini, A.; Bernardini, A.; Valent, F.; Fabris, M.; Curcio, F.; Brigo, F.; et al. Epidemiology of paraneoplastic neurological syndromes: A population-based study. J. Neurol. 2020, 267, 26–35. [CrossRef] [PubMed]
3. Graus, F.; Delattre, J.Y.; Antoine, J.C.; Dalmau, J.; Giometto, B.; Grisold, W.; Honnorat, J.; Smitt, P.S.; Vedeler, C.; Verschuuren, J.J.; et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry 2004, 75, 1135–1140. [CrossRef] [PubMed]
4. Dai, Y.; Zhang, J.; Ren, H.; Zhou, X.; Chen, J.; Cui, L.; Lang, J.; Guan, H.; Sun, D. Surgical outcomes in patients with anti-N-methyl
D-aspartate receptor encephalitis with ovarian teratoma. Am. J. Obstet. Gynecol. 2019, 221, e1–e10. [CrossRef] [PubMed]

5. Baizabal-Carvallo, J.F.; Jankovic, J. Autoimmune and paraneoplastic movement disorders: An update. J. Neurol. Sci. 2018, 385, 175–184. [CrossRef] [PubMed]

6. Dalmau, J.; Rosenfeld, M.R. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008, 7, 327–340. [CrossRef]

7. Galli, J.; Greenlee, J. Paraneoplastic Diseases of the Central Nervous System. F1000Research 2020, 9, F1000. [CrossRef] [PubMed]

8. Titulaer, M.J.; Soffietti, R.; Dalmau, J.; Gilhus, N.E.; Giometto, B.; Graus, F.; Grisold, W.; Honnorat, J.; Sillevis Smitt, P.A.; Tanasescu, R.; et al. Screening for tumours in paraneoplastic syndromes: Report of an EFNS task force. European Federation of Neurological Societies. Eur. J. Neurol. 2011, 18, 19-e3. [CrossRef] [PubMed]

9. Galli, J.; Greenlee, J. Paraneoplastic Diseases of the Central Nervous System. F1000Research 2020, 9, F1000. [CrossRef] [PubMed]

10. Sheikhbahaei, S.; Marcus, C.V.; Fragomeni, R.S.; Rowe, S.P.; Javadi, M.S.; Solnes, L.B. Whole-Body 18F-FDG PET and 18F-FDG PET/CT in Patients with Suspected Paraneoplastic Syndrome: A Systematic Review and Meta-Analysis of Diagnostic Accuracy. J. Nucl. Med. 2017, 58, 1031–1036. [CrossRef] [PubMed]

11. Vedeler, C.A.; Antoine, J.C.; Giometto, B.; Graus, F.; Grisold, W.; Hart, I.K.; Honnorat, J.; Sillevis Smitt, P.A.; Verschuuren, J.J.; Voltz, R. Management of Paraneoplastic Syndromes: Report of an EFNS Task Force. Paraneoplastic Neurological Syndrome Euronetwork. Eur. J. Neurol. 2006, 13, 682–690. [CrossRef] [PubMed]

12. Harlos, C.; Metser, U.; Poon, R.; MacCrostie, P.; Mason, W. 18 F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or indeterminate conventional imaging: A retrospective analysis of the Ontario PET Access Program. with systematic review and meta-analysis. Curr. Oncol. 2019, 26, e458–e465. [CrossRef] [PubMed]

13. Vatankulu, B.; Aksoy, S.Y.; Asa, S.; Sager, S.; Sayman, H.B.; Halac, M.; Sonmezoglu, K. Vccuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes. Rev. Esp. Med. Nucl. Imagen Mol. 2016, 35, 17–21. [CrossRef] [PubMed]

14. García Vicente, A.M.; Delgado-Bolton, R.C.; Amo-Salas, M.; López-Fidalgo, J.; Caresia Aróztegui, A.P.; García Garzón, J.R.; Orcajo Rincón, J.; García Veloso, M.J.; de Arcocha Torres, M.; Álvarez Ruiz, S. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of malignancy in patients with paraneoplastic neurological syndrome: A systematic review and meta-analysis. Oncology Task Force of Spanish Society of Nuclear Medicine and Molecular Imaging. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 1575–1587. [CrossRef] [PubMed]